DRUG — Bright Minds Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- CA$641.94m
- CA$590.69m
- 26
- 25
- 89
- 44
Annual balance sheet for Bright Minds Biosciences, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.8 | 19.8 | 11.6 | 6.75 | 5.72 |
| Net Total Receivables | — | 0.11 | 0.156 | 0.037 | 0.05 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.878 | 20 | 11.9 | 6.81 | 5.99 |
| Net Property, Plant And Equipment | — | — | 0.139 | 0.066 | 0.118 |
| Net Intangible Assets | |||||
| Total Assets | 0.88 | 20 | 12.1 | 6.88 | 6.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.151 | 0.639 | 1.47 | 0.281 | 0.529 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.151 | 0.639 | 1.54 | 0.281 | 0.568 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.729 | 19.4 | 10.5 | 6.6 | 5.54 |
| Total Liabilities & Shareholders' Equity | 0.88 | 20 | 12.1 | 6.88 | 6.1 |
| Total Common Shares Outstanding |